JPRN-jRCTs031180119已完成未知
Prospective randomized study of safety outcomes treated with Edioxaban in patients with stable coronary artery disease and atrial fibrillation - PRAEDO AF study
Fukamachi Daisuke0 个研究点目标入组 147 人开始时间: 2019年2月13日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 147
研究概览
简要总结
The study found clinical acceptance of edoxaban monotherapy in patients with ischemic heart disease with atrial fibrillation 6 months after coronary artery treatment.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients with non-valvular atrial fibrillation complicated with stable coronary artery disease who are 20 years or more at the obtaining of informed consent. CHADS2 score are 1 or more, and fulfil the criteria below and can provide written consent for participation in the present study will be eligible.
- •1) Patients who underwent percutaneous coronary intervention, including plain old balloon angioplasty. At least six months ago
- •2) Patients who have coronary stenosis requiring no percutaneous coronary intervention (50% or more stenosis) as indicated by coronary CT or coronary angiography
- •3) Patients who underwent coronary artery bypass graft CABG at least six months ago
排除标准
- •1) Patients who are contraindicated for Edoxaban
- •2) Patients who are contraindicated for Clopidgrel
- •3) Patients who are going to undergo revascularization
- •4) Those who are going undergo invasive surgery (excluding digestive endoscopy and biopsy
- •5) Patients who have active tumors
- •6) Patients who have poorly-controlled hypertension (systolic blood
- •pressure at hospital admission:160mmHg or more)
- •7) Patients judged as inappropriate for this study by investigators
研究者
相似试验
已完成
不适用
Evaluation of Treatment Safety in Patients With Atrial Fibrillation on Edoxaban Therapy in Real-Life in TurkeyAtrial FibrillationNCT04594915Daiichi Sankyo Turkey, a Daiichi Sankyo Company1,053
已完成
不适用
Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Hong Kong)Atrial FibrillationNCT03247582Daiichi Sankyo Hong Kong Ltd., a Daiichi Sankyo Company234
已完成
不适用
Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation (NVAF)Atrial FibrillationNCT03247569Daiichi Sankyo (Thailand) Ltd., a Daiichi Sankyo Company300
已完成
3 期
Study of DU-176b Aged 80 Years or OlderAtrial FibrillationNCT02801669Daiichi Sankyo Co., Ltd.984
已完成
3 期
Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary InterventionAtrial FibrillationNCT02866175Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1,506